← Search & browse all drugs

isepamicin

J01GB11

Forms & Strengths

Injectable solution: 50 mg/mL
Injectable solution: 100 mg/mL
Intravenous infusion vials: 200 mg
Intravenous infusion vials: 400 mg

Adult Dosing

Complicated urinary tract infections: 8-15 mg/kg/day divided every 12 to 24 hours IV/IM
Serious systemic bacterial infections: 15 mg/kg/day divided every 12 to 24 hours IV/IM
Adjust dose based on renal function and therapeutic drug monitoring

Pediatric Dosing

Safety and efficacy in pediatric patients not well established
Use generally restricted to serious infections where safer alternatives are ineffective: 7.5 to 15 mg/kg/day divided every 8 to 12 hours IV/IM

Indications

Treatment of serious bacterial infections caused by susceptible Gram-negative bacilli
Complicated and recurrent urinary tract infections
Lower respiratory tract infections
Septicemia and intra-abdominal infections

Mechanism of Action

Semi-synthetic aminoglycoside antibiotic
Binds irreversibly to the 30S ribosomal subunit of susceptible bacteria
Inhibits protein synthesis and causes misreading of the genetic code
Exhibits concentration-dependent bactericidal activity

Contraindications

Hypersensitivity to isepamicin or other aminoglycosides
History of severe hypersensitivity or toxic reactions to aminoglycosides

Adverse Reactions

Nephrotoxicity (elevated serum creatinine, blood urea nitrogen)
Ototoxicity (auditory damage, vestibular toxicity, tinnitus, hearing loss)
Neurotoxicity and neuromuscular blockade
Injection site reactions, rash, nausea, and elevated liver enzymes

Drug Interactions

Increased risk of nephrotoxicity with concurrent potent diuretics (e.g., furosemide)
Enhanced nephrotoxicity and ototoxicity with other aminoglycosides, vancomycin, or amphotericin B
Prolonged neuromuscular blockade when co-administered with neuromuscular blocking agents
Potentiation of nephrotoxic effects when combined with platinum-based chemotherapeutic agents

Curated Content: Needs Vetting Before Put to Clinical Use